SEC Form 8-K Summary
Business context and reporting period
This Form 8-K was filed by Eliem Therapeutics, Inc., not Climb Bio, Inc., on August 12, 2021. The filing reports corporate governance actions taken in connection with the closing of the company’s initial public offering. Eliem’s common stock traded on Nasdaq under the symbol ELYM.
Financial metrics and liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, capitalization, or other operating financial metrics.
Material changes
- The company filed an amended and restated certificate of incorporation with the Delaware Secretary of State, effective upon the closing of its initial public offering.
- The company adopted amended and restated bylaws effective August 12, 2021, also in connection with the initial public offering.
- The governing documents had previously been approved by the board of directors and stockholders.
Guidance, outlook, risks, and unusual items
The filing provides no financial guidance, operating outlook, risk update, contingencies, or unusual financial items. It refers investors to the company’s final prospectus dated August 9, 2021, filed on August 11, 2021, for descriptions of the amended governance documents and capital stock.
Investor verification points
- Verify the issuer identity: the supplied filing text identifies Eliem Therapeutics, Inc., while the request metadata identifies Climb Bio, Inc.
- Review Exhibits 3.1 and 3.2 for the complete amended and restated certificate of incorporation and bylaws.
- Review the August 11, 2021 final prospectus for IPO terms, capitalization, use of proceeds, risk factors, and related financial information.
- Confirm the effective date and terms of the IPO and the resulting corporate governance provisions.